Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Therapeutics presented Phase 2 data for ALXN1840 at EASL 2026, showing stabilization of liver pathology and significant neurologic improvement in treatment-experienced Wilson disease patients. Among 24 patients with paired biopsies, the majority showed stabilization or improvement in key histologic measures, including 96% for hepatocyte necrosis and 67% for fibrosis stage, after 48 weeks of monotherapy.
Key figures
- Drug Name
- ALXN1840 (tiomolibdate choline)
- Phase Of Trial
- Phase 2
- Cgi p value
- <0.05
- Eq5d p value
- <0.05
- Patient count
- 29
- Paired biopsies
- 24
- Study duration weeks
- 48
- Uwdrs part iii p value
- <0.05
- Median prior treatment years
- 13.8
- Fibrosis stage stabilization pct
- 67
- Steatosis grade stabilization pct
- 88
- Hepatocyte necrosis stabilization pct
- 96
- Portal inflammation stabilization pct
- 71
- Lobular inflammation stabilization pct
- 79
- Nafld activity score stabilization pct
- 71
- Hepatocellular ballooning stabilization pct
- 75
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.